NYSE:MED Medifast (MED) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free MED Stock Alerts $38.50 +0.97 (+2.58%) (As of 03:40 PM ET) Add Compare Share Share Today's Range$37.50▼$39.0050-Day Range$34.59▼$56.9652-Week Range$34.09▼$109.52Volume213,075 shsAverage Volume386,492 shsMarket Capitalization$419.65 millionP/E Ratio4.23Dividend YieldN/APrice Target$61.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Medifast alerts: Email Address Medifast MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside58.3% Upside$61.00 Price TargetShort InterestBearish19.34% of Float Sold ShortDividend StrengthN/ASustainability-4.17Upright™ Environmental ScoreNews Sentiment0.34Based on 5 Articles This WeekInsider TradingSelling Shares$159,850 Sold Last QuarterProj. Earnings Growth40.45%From $3.56 to $5.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.13 out of 5 starsConsumer Staples Sector39th out of 134 stocksMiscellaneous Food Preparations & Kindred Products Industry1st out of 4 stocks 3.0 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $61.00, Medifast has a forecasted upside of 58.3% from its current price of $38.54.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.34% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Medifast has recently increased by 5.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast has only been increasing its dividend for 1 years. Previous Next 1.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a -5.63% net impact score from Upright. The largest negative impact of Medifast in category "GHG emissions" seems to be driven mostly by its "Meal replacement soups", "Meal replacement bars", "Meal replacement drinks", and "Protein bars" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -4.17. Previous Next 1.9 News and Social Media Coverage News SentimentMedifast has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medifast this week, compared to 4 articles on an average week.Search InterestOnly 23 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $159,850.00 in company stock.Percentage Held by InsidersOnly 2.06% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 40.45% in the coming year, from $3.56 to $5.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 4.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.84.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 4.23, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 20.27.Price to Book Value per Share RatioMedifast has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Medifast Stock (NYSE:MED)Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More MED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MED Stock News HeadlinesMarch 19, 2024 | marketbeat.comLifeMD Shares Come Back to Life on GLP-1 Business Growth (MED)LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024March 12, 2024 | insidertrades.comInsider Selling: Medifast, Inc. (NYSE:MED) Director Sells 4,053 Shares of StockMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 28, 2024 | msn.comOptavia Diet Review 2024: Does This Program Really Work for Weight Loss?March 28, 2024 | finance.yahoo.comQ4 Rundown: BeautyHealth (NASDAQ:SKIN) Vs Other Personal Care StocksMarch 21, 2024 | finance.yahoo.comMEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?March 20, 2024 | seekingalpha.comMedifast: Cheap Valuation, Uncertain FutureMarch 16, 2024 | finance.yahoo.comMED Apr 2024 20.000 putMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 14, 2024 | finance.yahoo.comShould You Think About Buying Medifast, Inc. (NYSE:MED) Now?March 14, 2024 | seekingalpha.comLifeMD: Results And Guidance Point To Continued Strength In Weight Management ProgramMarch 13, 2024 | markets.businessinsider.comRobust Growth and Strategic Partnerships Reinforce Buy Rating for LifeMDMarch 12, 2024 | gurufocus.comDirector Scott Schlackman Sells Shares of Medifast Inc (MED)March 12, 2024 | msn.comLifeMD, Inc. (NASDAQ:LFMD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | finanznachrichten.deLifeMD, Inc.: LifeMD Reports Fourth Quarter 2023 ResultsMarch 8, 2024 | finance.yahoo.comMED Jun 2024 52.500 callMarch 7, 2024 | investorplace.comHey, Bottom Fishers! 3 Beaten Up Stocks to Buy for Short-Term GainsMarch 7, 2024 | seekingalpha.comMedifast Is Getting AttractiveMarch 7, 2024 | finance.yahoo.comMED Apr 2024 27.500 putMarch 7, 2024 | finance.yahoo.comMED Nov 2024 52.500 putMarch 1, 2024 | 247wallst.comWant $10,000 in Passive Income? Invest $2,000 in Each of These Dividend StocksFebruary 28, 2024 | 247wallst.comDon't Get Near These 10%+ Dividend Yield StocksFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Consumer Cyclical Companies: CarGurus (CARG), Lowe’s (LOW) and Medifast (MED)February 23, 2024 | finance.yahoo.comAnalysts Are More Bearish On Medifast, Inc. (NYSE:MED) Than They Used To BeFebruary 22, 2024 | bizjournals.comBaltimore public company sees revenue drop 32.9% in a yearFebruary 22, 2024 | finance.yahoo.comMedifast Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 21, 2024 | marketwatch.comMedifast Shares Drop 16% After Lower 4Q EarningsSee More Headlines Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today3/28/2024Next Earnings (Estimated)5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees634Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$82.00 Low Stock Price Target$40.00 Potential Upside/Downside+59.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$9.11 Trailing P/E Ratio4.21 Forward P/E Ratio10.76 P/E GrowthN/ANet Income$99.42 million Net Margins9.27% Pretax Margin12.01% Return on Equity56.06% Return on Assets33.14% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio1.84 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.39 Cash Flow$11.20 per share Price / Cash Flow3.42 Book Value$18.50 per share Price / Book2.07Miscellaneous Outstanding Shares10,900,000Free Float10,672,000Market Cap$417.58 million OptionableOptionable Beta1.15 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Daniel R. Chard (Age 59)Executive Chairman & CEO Comp: $1.94MMr. James P. Maloney CPA (Age 56)Chief Financial Officer Comp: $823.91kMr. Anthony E. Tyree (Age 59)Chief Business Operations Officer Comp: $655.86kMr. Jason L. Groves Esq. (Age 53)Executive VP, General Counsel & Corporate Secretary Comp: $669.51kMr. Nicholas M. Johnson (Age 44)Chief Field Operations Officer Comp: $696.4kMr. Jonathan Barrett MacKenzie (Age 52)VP of Finance & Chief Accounting Officer Mr. Steven ZenkerVice President of Investor RelationsMs. Claudia C. Greninger (Age 51)Chief Human Resources Officer More ExecutivesKey CompetitorsCarriage ServicesNYSE:CSVSeneca FoodsNASDAQ:SENEALimoneiraNASDAQ:LMNRCibusNASDAQ:CBUSDaily JournalNASDAQ:DJCOView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 1,036 shares on 3/22/2024Ownership: 0.010%Vanguard Group Inc.Bought 113,734 shares on 3/11/2024Ownership: 15.477%Scott SchlackmanSold 4,053 sharesTotal: $159,850.32 ($39.44/share)Goldman Sachs Group Inc.Bought 15,713 shares on 3/1/2024Ownership: 0.345%Scarborough Advisors LLCBought 11,642 shares on 2/22/2024Ownership: 0.107%View All Insider TransactionsView All Institutional Transactions MED Stock Analysis - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price target for 2024? 2 brokerages have issued 1 year price targets for Medifast's shares. Their MED share price targets range from $40.00 to $82.00. On average, they expect the company's share price to reach $61.00 in the next twelve months. This suggests a possible upside of 58.3% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2024? Medifast's stock was trading at $67.22 on January 1st, 2024. Since then, MED shares have decreased by 42.7% and is now trading at $38.54. View the best growth stocks for 2024 here. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024. View our MED earnings forecast. How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Tuesday, February, 20th. The specialty retailer reported $1.09 EPS for the quarter, beating the consensus estimate of $0.99 by $0.10. The specialty retailer earned $191.02 million during the quarter, compared to analysts' expectations of $184.17 million. Medifast had a trailing twelve-month return on equity of 56.06% and a net margin of 9.27%. The firm's revenue was down 43.4% compared to the same quarter last year. During the same period last year, the firm earned $3.70 EPS. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast declared a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be given a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 17.13%. The ex-dividend date is Monday, September 18th. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), First Trust SMID Cap Rising Dividend Archievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap Quality ETF (XSHQ), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Royce Quant Small-Cap Quality Value ETF (SQLV) and Global X Health & Wellness ETF (BFIT). What guidance has Medifast issued on next quarter's earnings? Medifast issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided EPS guidance of 0.250-0.950 for the period, compared to the consensus EPS estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). Who are Medifast's major shareholders? Medifast's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (15.49%), Vanguard Group Inc. (15.48%), Pacer Advisors Inc. (4.80%), First Trust Advisors LP (3.65%), Dimensional Fund Advisors LP (2.85%) and Charles Schwab Investment Management Inc. (1.71%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:MED) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.